Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07314203) titled 'Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer' on Dec. 18, 2025.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fujian Medical University
Condition:
Gastric Cancer
Surgery
Intervention:
Drug: Apatinib Mesylate Tablets
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: December 25, 2026
Target Sample Size: 118
Countries of Recruitment:
China
To know more, visit https:/...